Literature DB >> 2436048

A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army.

L B Seeff, G W Beebe, J H Hoofnagle, J E Norman, Z Buskell-Bales, J G Waggoner, N Kaplowitz, R S Koff, J L Petrini, E R Schiff.   

Abstract

An epidemic of icteric hepatitis in 1942 affected approximately 50,000 U.S. Army personnel. This outbreak was linked to specific lots of yellow-fever vaccine stabilized with human serum. To identify the responsible virus and the consequences of the epidemic, during 1985 we interviewed and serologically screened 597 veterans who had been in the army in 1942. These subjects were selected from three groups. Group I consisted of patients who had received the implicated vaccine and had jaundice; Group II had received the implicated vaccine but remained well; Group III had received a new, serum-free vaccine, with no subsequent jaundice. Ninety-seven percent of Group I, 76 percent of Group II, and 13 percent of Group III were positive for antibodies to hepatitis B virus. Only one subject had hepatitis B surface antigen, for a carrier rate of 0.26 percent among recipients of the implicated vaccine. The prevalence of hepatitis A antibody was similar in all three groups, and no subject had antibody to hepatitis delta virus. We conclude that hepatitis B caused the outbreak, that about 330,000 persons may have been infected, that the hepatitis B virus carrier state was a rare consequence, and that the outbreak induced hepatitis B antibodies that appear to persist for life.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2436048     DOI: 10.1056/NEJM198704163161601

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  39 in total

1.  Yellow fever vaccine.

Authors:  Philip P Mortimer
Journal:  BMJ       Date:  2002-02-23

Review 2.  Current and Future Burden of Chronic Nonmalignant Liver Disease.

Authors:  Prowpanga Udompap; Donghee Kim; W Ray Kim
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-17       Impact factor: 11.382

3.  Recent epidemiological and clinical features of acute hepatitis B in a single center of China.

Authors:  Xiaohong Chen; Chengtao Fu; Jia Liu; Lei Shan; Chenglin Liu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

4.  Improvements in detection of antibody to hepatitis B core antigen by treating specimens with reducing agent in an automated microparticle enzyme immunoassay.

Authors:  A M Spronk; L Schmidt; C Krenc; L Pavlis-Jenkins; J Brady; S Taskar; L Angus-Finn; L Mimms
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

Review 5.  Viral hepatitis: past and future of HBV and HDV.

Authors:  Emmanuel Thomas; Masato Yoneda; Eugene R Schiff
Journal:  Cold Spring Harb Perspect Med       Date:  2015-02-02       Impact factor: 6.915

6.  Cigarette smoking and liver cancer among US veterans.

Authors:  A W Hsing; J K McLaughlin; Z Hrubec; W J Blot; J F Fraumeni
Journal:  Cancer Causes Control       Date:  1990-11       Impact factor: 2.506

Review 7.  Advances and controversies in yellow fever vaccination.

Authors:  Emile F F Jonker; Leonardus G Visser; Anna H Roukens
Journal:  Ther Adv Vaccines       Date:  2013-11

Review 8.  Mortality and morbidity among military personnel and civilians during the 1930s and World War II from transmission of hepatitis during yellow fever vaccination: systematic review.

Authors:  Roger E Thomas; Diane L Lorenzetti; Wendy Spragins
Journal:  Am J Public Health       Date:  2013-01-17       Impact factor: 9.308

9.  Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China.

Authors:  David W Hutton; Samuel K So; Margaret L Brandeau
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

10.  Time trend of the prevalence of hepatitis E antibodies among farmers and blood donors: a potential zoonosis in Denmark.

Authors:  Peer B Christensen; Ronald E Engle; Charlotte Hjort; Keld M Homburg; Werner Vach; Jørgen Georgsen; Robert H Purcell
Journal:  Clin Infect Dis       Date:  2008-10-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.